Applied Therapeutics, a trial sponsor, failed to let FDA access deleted electronic trial data and omitted dosing-error information from its drug application.
What happened
FDA inspected Applied Therapeutics as sponsor of a clinical investigation from April 29 to May 3, 2024. FDA found that a third-party vendor deleted Q-global electronic clinical outcome assessment data and audit trails for all 47 subjects two days after FDA preannounced a site inspection, so FDA could not verify the data. FDA also found that the company did not tell FDA in its new drug application about a mislabeled drug concentration that caused at least 19 subjects to receive 80% of the protocol-required dose.
What FDA found
Applied Therapeutics did not let FDA access, copy, and verify records and reports for its clinical investigation, because critical electronic eCOA data and audit trails were deleted and unavailable.
21 CFR 312.58Applied Therapeutics did not give FDA a description and analysis of relevant safety and effectiveness information, because it did not disclose dosing errors from a mislabeled drug concentration in its application.
21 CFR 314.50(d)(5)(iv)
What FDA wants
FDA asks Applied Therapeutics to respond in writing within 15 business days describing actions taken to prevent similar violations and to address the deficiencies, including sufficient details of its corrective action plan.
Who should pay attention
- clinical trial sponsors and contract research organizations
- companies using third-party electronic data systems for trials
- drug applicants submitting clinical study data to FDA
This is a summary. Read the original letter on fda.gov.